Latest filing published 15 Nov 2013 for Madrigal Pharmaceuticals, INC., €56k.
Insider track record
No signal scores available.
Closed purchases
Based on 18 purchases whose 90-day window has closed (published at least 91 days ago), the same population our ranking model reads.
Purchases by company
Since each purchase
- -33.7%Entry US$170.45 · Close at T+365 US$113.05
- -11.2%Entry US$177.45 · Close at T+365 US$157.50
- -12.4%Entry US$164.15 · Close at T+365 US$143.85
- +11.9%Entry US$135.80 · Close at T+365 US$151.90
- -4.8%Entry US$154.70 · Close at T+365 US$147.35
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Safi R. Bahcall: trading record in brief
Safi R. Bahcall appears in our data through filings on Madrigal Pharmaceuticals, Inc. shares, published by SEC (Form 4). In total, 22 filings cover trades dated from 26 November 2007 to 13 November 2013.
No open-market sale appears; the market trades are 18 purchases worth €493k. A purchase on the market is a deliberate choice to commit personal money, which is why it draws more attention than a grant. The rest of the record consists of 4 share grants. So far in 2013, the count stands at 5 purchases and no sales.
In size, the median ticket on the buying side is €26k. For 18 purchases whose 90-day window has closed, the share price was higher on day 90 than the day after publication in 78% of cases, with a median move of +12.2%. Past outcomes like these are no guarantee of what comes next.
On 15 November 2013 came the latest disclosure, an open-market purchase for €56k in Madrigal Pharmaceuticals, Inc. Filings reach the SEC (Form 4) feed a median of 1 day after the trade. For comparison, the SEC allows two business days to file a Form 4. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.
Companies and markets linked to Safi R. Bahcall
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
- 20,000 shares@ US$3.75Common StockSEC:0001179110-13-016610:0Canonical exit: 11 Feb 2014 (T+90)
- 10,000 shares@ US$5.03Common StockSEC:0001179110-13-011095:0Canonical exit: 26 Sept 2013 (T+90)
- 20,000 shares@ US$4.12Common StockSEC:0001179110-13-010743:0Canonical exit: 19 Sept 2013 (T+90)
- 10,000 shares@ US$4.06Common StockSEC:0001179110-13-010426:0Canonical exit: 12 Sept 2013 (T+90)
- 10,000 shares@ US$4.04Common StockSEC:0001179110-13-009876:0Canonical exit: 4 Sept 2013 (T+90)
- 10,000 shares@ US$8.60Common StockSEC:0001179110-12-017619:0
- 10,000 shares@ US$7.12Common StockSEC:0001179110-12-015902:0Canonical exit: 10 Feb 2013 (T+90)
- 20,000 shares@ US$6.49Common StockSEC:0001179110-12-011906:0
- 10,000 shares@ US$5.34Common StockSEC:0001179110-12-010917:0Canonical exit: 27 Sept 2012 (T+90)
- 5,000 shares@ US$4.45Common StockSEC:0001179110-11-004911:0Canonical exit: 13 Jun 2011 (T+90)
- 11,549 shares0Common StockSEC:0001179110-11-004064:0
- 10,000 shares@ US$3.05Common StockSEC:0001179110-10-010256:0Canonical exit: 8 Sept 2010 (T+90)
- 13,839 shares0Common StockSEC:0001179110-10-004341:0
- 22,222 shares@ US$4.50Common StockSEC:0001179110-10-000892:0Canonical exit: 8 Apr 2010 (T+90)
- 200 shares@ US$2.78Common StockSEC:0001179110-09-011745:0Canonical exit: 4 Nov 2009 (T+90)
- 6,079 shares@ US$2.80Common StockSEC:0001179110-09-011745:1Canonical exit: 4 Nov 2009 (T+90)
- 300 shares@ US$2.82Common StockSEC:0001179110-09-011745:2Canonical exit: 4 Nov 2009 (T+90)
- 1,980 shares@ US$2.83Common StockSEC:0001179110-09-011745:3Canonical exit: 4 Nov 2009 (T+90)
- 2,000 shares@ US$2.85Common StockSEC:0001179110-09-011745:4Canonical exit: 4 Nov 2009 (T+90)
- 196 shares@ US$2.88Common StockSEC:0001179110-09-011745:5Canonical exit: 4 Nov 2009 (T+90)
- 9,245 shares@ US$2.89Common StockSEC:0001179110-09-011745:6Canonical exit: 4 Nov 2009 (T+90)
- 5,000 shares@ US$7.83Common StockSEC:0001179110-07-022177:0Canonical exit: 24 Feb 2008 (T+90)
22 of 22 declarations
